Optimax Access is a UK-based HEOR consultancy company. The company was founded in the UK in 2017, and since 2019 has been a part of the iGES Life Sciences Group, which itself was founded in 1980 and has become Germany’s leading private research institute for the public sector. Fully owned and operated by its more than 200 scientists, iGES has conducted over 2000 research and consulting projects.
Optimax Access can count on a multidisciplinary team of health economists, research analysts and clinicians with over 15 years of international experience in the healthcare industry. Their expertise and leadership in their various fields of research and health services are the foundation on which we have built our reputation and position at the forefront of the HEOR market. Our teams have conducted several projects since the company’s launch, including the release of 50 publications across over 14 disease areas between 2018-2020.
We offer our services to Pharma and MedTech organisations, with our clients ranging from small to top 10 pharmaceutical, Biotech and MedTech companies. Our headquarters are in Southampton, UK and we also have offices in the Netherlands, Canada and the U.S to cater to an international clientele. We offer our services worldwide and work to secure reimbursement for our clients’ innovative products and services across major healthcare markets on local, regional, national and global scales.
We collaborate with our sister companies within the iGES Life Sciences Group to offer our clients the best services in HEOR. Our sister companies in Europe are:
– Belgium and France: MediTech Access Company,
– Switzerland: HealthEcon Company,
– United Kingdom: Device Access Company.
